164 related articles for article (PubMed ID: 31698007)
21. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemistry in diagnostic surgical pathology of the prostate.
Hameed O; Humphrey PA
Semin Diagn Pathol; 2005 Feb; 22(1):88-104. PubMed ID: 16512601
[TBL] [Abstract][Full Text] [Related]
23. Prostate carcinoma with squamous differentiation: an analysis of 33 cases.
Parwani AV; Kronz JD; Genega EM; Gaudin P; Chang S; Epstein JI
Am J Surg Pathol; 2004 May; 28(5):651-7. PubMed ID: 15105655
[TBL] [Abstract][Full Text] [Related]
24. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
25. Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases.
Osunkoya AO; Hansel DE; Sun X; Netto GJ; Epstein JI
Am J Surg Pathol; 2008 Mar; 32(3):461-7. PubMed ID: 18300803
[TBL] [Abstract][Full Text] [Related]
26. PIN-like (Ductal) Adenocarcinoma of the Prostate.
Paulk A; Giannico G; Epstein JI
Am J Surg Pathol; 2018 Dec; 42(12):1693-1700. PubMed ID: 30138215
[TBL] [Abstract][Full Text] [Related]
27. [A case of prostate cancer diagnosed pathologically by bone metastatic site biopsy].
Nakata S; Nakano K; Takahashi H; Shimizu K; Higashi H; Ohki K
Nihon Hinyokika Gakkai Zasshi; 2005 May; 96(4):507-10. PubMed ID: 15948412
[TBL] [Abstract][Full Text] [Related]
28. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
29. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer.
Aprikian AG; Fair WR; Reuter VE; Sogani P; Herr H; Russo P; Sheinfeld J
Br J Urol; 1994 Nov; 74(5):630-6. PubMed ID: 7530128
[TBL] [Abstract][Full Text] [Related]
30. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
Stock RG; Stone NN; Ianuzzi C; Unger P
Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
[TBL] [Abstract][Full Text] [Related]
31. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
[TBL] [Abstract][Full Text] [Related]
32. [Clinical characteristics of prostatic adenocarcinoma with ductal features].
Yamashita R; Matsuzaki M; Matsui T; Yamaguchi R; Yuen K; Niwakawa M; Tobisu K
Nihon Hinyokika Gakkai Zasshi; 2008 Mar; 99(3):525-30. PubMed ID: 18404881
[TBL] [Abstract][Full Text] [Related]
33. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases.
Darson MF; Pacelli A; Roche P; Rittenhouse HG; Wolfert RL; Saeid MS; Young CY; Klee GG; Tindall DJ; Bostwick DG
Urology; 1999 May; 53(5):939-44. PubMed ID: 10223487
[TBL] [Abstract][Full Text] [Related]
34. Immunoreactivity for prostate-specific antigen and prostatic acid phosphatase in adenocarcinoma of the prostate: relation to progression following radical prostatectomy.
Sauvageot J; Epstein JI
Prostate; 1998 Jan; 34(1):29-33. PubMed ID: 9428385
[TBL] [Abstract][Full Text] [Related]
35. Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report.
Kitamura J; Taguchi S; Okegawa T; Honda K; Kii T; Tomida Y; Matsumoto R; Ninomiya N; Masuda K; Nakamura Y; Yamaguchi T; Kinjo M; Tambo M; Isomura A; Hayashi A; Kamma H; Higashihara E; Shibahara J; Fukuhara H
BMC Med Genomics; 2021 Sep; 14(1):217. PubMed ID: 34479548
[TBL] [Abstract][Full Text] [Related]
36. Basal cell carcinoma of the prostate: clinicopathologic analysis of three cases and a review of the literature.
Chang K; Dai B; Kong Y; Qu Y; Wu J; Ye D; Yao X; Zhang S; Zhang H; Zhu Y; Yao W
World J Surg Oncol; 2013 Aug; 11(1):193. PubMed ID: 23941693
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic challenges of clonal heterogeneity in prostate cancer.
Haffner MC; De Marzo AM; Yegnasubramanian S; Epstein JI; Carter HB
J Clin Oncol; 2015 Mar; 33(7):e38-40. PubMed ID: 24638011
[No Abstract] [Full Text] [Related]
38. Incidence, location, and significance of periprostatic and periseminal vesicle lymph nodes in prostate cancer.
Kothari PS; Scardino PT; Ohori M; Kattan MW; Wheeler TM
Am J Surg Pathol; 2001 Nov; 25(11):1429-32. PubMed ID: 11684961
[TBL] [Abstract][Full Text] [Related]
39. Malignant priapism secondary to adenocarcinoma of the prostate.
Kitley CA; Mosier AD; Keylock J; Nguyen D
BMJ Case Rep; 2010 Oct; 2010():. PubMed ID: 22789733
[TBL] [Abstract][Full Text] [Related]
40. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment.
Gilani S; Guo CC; Li-Ning EM; Pettaway C; Troncoso P
Hum Pathol; 2017 Jun; 64():186-190. PubMed ID: 28159676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
